- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06345729
Een onderzoek naar MK-1084 plus Pembrolizumab (MK-3475) bij deelnemers met KRAS G12C-mutante, gemetastaseerde niet-kleincellige longkanker (NSCLC) met geprogrammeerde celdood Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)
Een fase 3, gerandomiseerde, dubbelblinde, multicentrische studie van MK-1084 in combinatie met Pembrolizumab vergeleken met Pembrolizumab plus Placebo als eerstelijnsbehandeling van deelnemers met KRAS G12C-mutant, gemetastaseerd NSCLC met PD-L1 TPS ≥50%
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis:
Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Per Protocol Amendment 04, overall survival (OS) was moved to be a secondary outcome measure. Additionally, no new participants will be offered Second Course treatment for pembrolizumab.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Toll Free Number
- Telefoonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studie Locaties
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Argentinië, B1884BBF
- Werving
- Centro de Oncología e Investigación de Buenos Aires ( Site 0308)
-
Contact:
- Study Coordinator
- Telefoonnummer: +541142262013
-
CABA, Buenos Aires, Argentinië, C1019ABS
- Voltooid
- AUSTRAL MEDICAL CENTER ( Site 0302)
-
CABA, Buenos Aires, Argentinië, C1426AGE
- Werving
- Centro Oncologico Korben ( Site 0304)
-
Contact:
- Study Coordinator
- Telefoonnummer: 1157507952
-
Mar del Plata, Buenos Aires, Argentinië, B7600FZO
- Werving
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300)
-
Contact:
- Study Coordinator
- Telefoonnummer: 02234963224
-
-
Río Negro Province
-
Viedma, Río Negro Province, Argentinië, R8500ACE
- Werving
- Clinica Viedma S. A ( Site 0307)
-
Contact:
- Study Coordinator
- Telefoonnummer: +54 2920 42-8700
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentinië, S2000DEJ
- Werving
- Fundacion Estudios Clinicos ( Site 0306)
-
Contact:
- Study Coordinator
- Telefoonnummer: +543412221472
-
Rosario, Santa Fe Province, Argentinië, S2000DSV
- Werving
- Sanatorio Parque ( Site 0301)
-
Contact:
- Study Coordinator
- Telefoonnummer: +54341420-0222
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australië, 2050
- Werving
- Chris O'Brien Lifehouse ( Site 3000)
-
Contact:
- Study Coordinator
- Telefoonnummer: +61285140140
-
-
Queensland
-
Urraween, Queensland, Australië, 4655
- Werving
- Cancer Care Service Hervey Bay ( Site 3003)
-
Contact:
- Study Coordinator
- Telefoonnummer: +610743256110
-
-
Victoria
-
Frankston, Victoria, Australië, 3199
- Werving
- Frankston Hospital ( Site 3002)
-
Contact:
- Study Coordinator
- Telefoonnummer: +61397847777
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- Werving
- One Clinical Research ( Site 3001)
-
Contact:
- Study Coordinator
- Telefoonnummer: +61862799466
-
-
-
-
-
Rio de Janeiro, Brazilië, 22775-001
- Werving
- Americas ( Site 0431)
-
Contact:
- Study Coordinator
- Telefoonnummer: +552133852088
-
Rio de Janeiro, Brazilië, 20230-130
- Werving
- Instituto Nacional de Câncer - INCA ( Site 0446)
-
Contact:
- Study Coordinator
- Telefoonnummer: +552132076564
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazilië, 30380-472
- Werving
- Hospital Mario Penna ( Site 0436)
-
Contact:
- Study Coordinator
- Telefoonnummer: +553132999543
-
-
Pernambuco
-
Recife, Pernambuco, Brazilië, 50040-000
- Werving
- Hospital de Câncer de Recife ( Site 0447)
-
Contact:
- Study Coordinator
- Telefoonnummer: +558132178084
-
-
Piauí
-
Teresina, Piauí, Brazilië, 64049-200
- Voltooid
- Oncoclínica Oncologistas Associados ( Site 0441)
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brazilië, 59062-000
- Werving
- Liga Norte Riograndense Contra o Câncer ( Site 0439)
-
Contact:
- Study Coordinator
- Telefoonnummer: +558440095595
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brazilië, 98700 000
- Werving
- Hospital de Caridade de Ijuí ( Site 0438)
-
Contact:
- Study Coordinator
- Telefoonnummer: +5555991221138
-
Passo Fundo, Rio Grande do Sul, Brazilië, 99010-260
- Werving
- Hospital de Clínicas de Passo Fundo ( Site 0442)
-
Contact:
- Study Coordinator
- Telefoonnummer: +5554981271411
-
Porto Alegre, Rio Grande do Sul, Brazilië, 90050-170
- Werving
- Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro Multidisciplinar de Pesquisa Clínica ( Site 0435)
-
Contact:
- Study Coordinator
- Telefoonnummer: +555132148143
-
-
São Paulo
-
Barretos, São Paulo, Brazilië, 14784-400
- Werving
- Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0437)
-
Contact:
- Study Coordinator
- Telefoonnummer: +551733216638
-
-
-
-
-
Pleven, Bulgarije, 5804
- Werving
- MHAT - Heart and Brain ( Site 1006)
-
Contact:
- Study Coordinator
- Telefoonnummer: +35988030371
-
Plovdiv, Bulgarije, 4000
- Werving
- Medical Center Futuremeds ( Site 1007)
-
Contact:
- Study Coordinator
- Telefoonnummer: +359886744494
-
Plovdiv, Bulgarije, 4004
- Werving
- Complex Oncology Center - Plovdiv EOOD ( Site 1003)
-
Contact:
- Study Coordinator
- Telefoonnummer: +359 32 277 240
-
-
Pazardzhik
-
Panagyurishte, Pazardzhik, Bulgarije, 4500
- Werving
- MBAL Uni Hospital-Department of Medical Oncology ( Site 1000)
-
Contact:
- Study Coordinator
- Telefoonnummer: +35935788581
-
-
Sofia (stolitsa)
-
Sofia, Sofia (stolitsa), Bulgarije, 1632
- Werving
- Multiprofile Hospital for Active Treatment SerdikaМЕD EOOD-Second Department of Medical Oncology ( Site 1002)
-
Contact:
- Study Coordinator
- Telefoonnummer: +35929049100
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Werving
- CancerCare Manitoba ( Site 0210)
-
Contact:
- Study Coordinator
- Telefoonnummer: 204-787-4156
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Werving
- QEII Health Sciences Centre - Victoria General Site-Dept. of Medical Oncology ( Site 0208)
-
Contact:
- Study Coordinator
- Telefoonnummer: 9024737964
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Werving
- Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0205)
-
Contact:
- Study Coordinator
- Telefoonnummer: 9053879495
-
Toronto, Ontario, Canada, M4N 3M5
- Werving
- Sunnybrook Research Institute ( Site 0206)
-
Contact:
- Study Coordinator
- Telefoonnummer: 4164805000x687435
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1M5
- Werving
- St. Marys Hospital Center ( Site 0204)
-
Contact:
- Study Coordinator
- Telefoonnummer: 5143453511
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Werving
- Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0207)
-
Contact:
- Study Coordinator
- Telefoonnummer: 8196973333x63238
-
-
-
-
Maule Region
-
Talca, Maule Region, Chili, 3465584
- Werving
- Clinica Universidad Catolica del Maule-Oncology ( Site 0500)
-
Contact:
- Study Coordinator
- Telefoonnummer: +56947532700
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chili, 7500713
- Werving
- Orlandi Oncologia-Oncology ( Site 0503)
-
Contact:
- Study Coordinator
- Telefoonnummer: +56226057491
-
Santiago, Region M. de Santiago, Chili, 7500921
- Werving
- FALP-UIDO ( Site 0501)
-
Contact:
- Study Coordinator
- Telefoonnummer: +56224205098
-
Santiago, Region M. de Santiago, Chili, 8420383
- Werving
- Bradfordhill-Clinical Area ( Site 0504)
-
Contact:
- Study Coordinator
- Telefoonnummer: +56229490970
-
Santiago, Region M. de Santiago, Chili, 7560913
- Werving
- Centro de Oncología de Precisión ( Site 0502)
-
Contact:
- Study Coordinator
- Telefoonnummer: 56991612199
-
-
-
-
Anhui
-
Hefei, Anhui, China, 230031
- Actief, niet wervend
- Anhui Provincial Cancer Hospital ( Site 3136)
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100142
- Actief, niet wervend
- Beijing Cancer hospital ( Site 3133)
-
Beijing, Beijing Municipality, China, 100142
- Actief, niet wervend
- Beijing Cancer hospital ( Site 3134)
-
Beijing, Beijing Municipality, China, 100730
- Actief, niet wervend
- Beijing Peking Union Medical College Hospital-pneumology department ( Site 3102)
-
Beijing, Beijing Municipality, China, 101149
- Actief, niet wervend
- Beijing Chest Hospital,Capital Medical University ( Site 3104)
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400030
- Actief, niet wervend
- Chongqing University Cancer Hospital ( Site 3119)
-
Chongqing, Chongqing Municipality, China, 400042
- Voltooid
- Army Medical Center of People's Liberation Army ( Site 3142)
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Actief, niet wervend
- Fujian Cancer Hospital ( Site 3127)
-
Xiamen, Fujian, China, 361003
- Actief, niet wervend
- The First Affiliated hospital of Xiamen University ( Site 3148)
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510160
- Voltooid
- The First Affiliated Hospital of Guangzhou Medical University ( Site 3108)
-
Guangzhou, Guangdong, China, 510515
- Actief, niet wervend
- Southern Medical University Nanfang Hospital ( Site 3128)
-
Guangzhou, Guangdong, China, 510555
- Voltooid
- Sun Yat-sen University Cancer Center ( Site 3137)
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Actief, niet wervend
- Harbin Medical University Cancer Hospital ( Site 3123)
-
Jiamusi, Heilongjiang, China, 154007
- Actief, niet wervend
- JIAMUSI TUBERCULOSIS HOSPITAL(CANCER HOSPITAL) ( Site 3124)
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Actief, niet wervend
- Henan Cancer Hospital ( Site 3149)
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Actief, niet wervend
- Tongji Hospital Tongji Medical,Science & Technology ( Site 3113)
-
Wuhan, Hubei, China, 430079
- Actief, niet wervend
- Hubei Cancer Hospital ( Site 3126)
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Voltooid
- The Second Xiangya Hospital of Central South University ( Site 3130)
-
Changsha, Hunan, China, 410013
- Actief, niet wervend
- Hunan Cancer Hospital ( Site 3141)
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Actief, niet wervend
- Nanjing Gulou Hospital ( Site 3122)
-
Nanjing, Jiangsu, China, 210012
- Voltooid
- Nanjing First Hospital ( Site 3154)
-
Suzhou, Jiangsu, China, 215006
- Voltooid
- The First Affiliated Hospital of Soochow University ( Site 3146)
-
Wuxi, Jiangsu, China, 214122
- Actief, niet wervend
- Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3155)
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Voltooid
- The Second Affiliated Hospital of Nanchang University ( Site 3139)
-
Nanchang, Jiangxi, China, 330006
- Actief, niet wervend
- The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3138)
-
-
Jilin
-
Changchun, Jilin, China, 130012
- Actief, niet wervend
- Jilin Province Tumor Hospital ( Site 3107)
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Voltooid
- The First Affiliated Hospital of Xi'an Jiaotong University ( Site 3150)
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Actief, niet wervend
- Shandong Cancer Hospital ( Site 3116)
-
Linyi, Shandong, China, 276001
- Actief, niet wervend
- LinYi Cancer Hospital ( Site 3111)
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200030
- Actief, niet wervend
- Shanghai Chest Hospital ( Site 3100)
-
Shanghai, Shanghai Municipality, China, 200032
- Actief, niet wervend
- Fudan University Shanghai Cancer Center ( Site 3144)
-
Shanghai, Shanghai Municipality, China, 200032
- Actief, niet wervend
- Zhongshan Hospital,Fudan University ( Site 3143)
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030000
- Actief, niet wervend
- Shanxi Cancer Hospital ( Site 3131)
-
Xian, Shanxi, China, 710038
- Voltooid
- The Second Affiliated Hospital of Air Force Medical University ( Site 3117)
-
Xian, Shanxi, China, 710038
- Actief, niet wervend
- The Second Affiliated Hospital of Air Force Medical University ( Site 3152)
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Actief, niet wervend
- West China Hospital, Sichuan University ( Site 3140)
-
Chengdu, Sichuan, China, 610031
- Actief, niet wervend
- The Third People's Hospital of Chengdu (CDTPH) ( Site 3157)
-
Chengdu, Sichuan, China, 610042
- Actief, niet wervend
- Sichuan Cancer hospital. ( Site 3109)
-
Neijiang, Sichuan, China, 641000
- Actief, niet wervend
- The Second People's Hospital of Neijiang ( Site 3105)
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830000
- Voltooid
- Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3101)
-
-
Yunnan
-
Kunming, Yunnan, China, 650107
- Actief, niet wervend
- Yunnan Province Cancer Hospital ( Site 3153)
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- Actief, niet wervend
- The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115)
-
Hangzhou, Zhejiang, China, 310016
- Actief, niet wervend
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3121)
-
Linhai, Zhejiang, China, 317000
- Actief, niet wervend
- Taizhou Hospital of Zhejiang Province ( Site 3145)
-
Wenzhou, Zhejiang, China, 325015
- Actief, niet wervend
- The First Affiliated Hospital of Wenzhou Medical University ( Site 3151)
-
-
-
-
Cesar Department
-
Valledupar, Cesar Department, Colombia, 200001
- Werving
- Sociedad De Oncología y Hematología Del Cesar SAS ( Site 4000)
-
Contact:
- Study Coordinator
- Telefoonnummer: +573122354788
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 110111
- Werving
- Clinica Oncologica Colsubsidio ( Site 4003)
-
Contact:
- Study Coordinator
- Telefoonnummer: +573142059194
-
-
Risaralda Department
-
Pereira, Risaralda Department, Colombia, 660001
- Werving
- Oncologos del Occidente ( Site 4005)
-
Contact:
- Study Coordinator
- Telefoonnummer: +57 3187715522
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 76001
- Werving
- Hemato Oncologos SA ( Site 4002)
-
Contact:
- Study Coordinator
- Telefoonnummer: +573167711932
-
-
-
-
-
San José, Costa Rica, 10103
- Werving
- Onco Tech, S.A. ( Site 4102)
-
Contact:
- Study Coordinator
- Telefoonnummer: +50622586260
-
-
-
-
Baden-Wurttemberg
-
Stuttgart, Baden-Wurttemberg, Duitsland, 70199
- Werving
- Marienhospital Stuttgart ( Site 1302)
-
Contact:
- Study Coordinator
- Telefoonnummer: +49711064893273
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Duitsland, 17489
- Werving
- Universitätsmedizin Greifswald ( Site 1308)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4938348622006
-
-
North Rhine-Westphalia
-
Bielefeld, North Rhine-Westphalia, Duitsland, 33611
- Werving
- Evangelisches Krankenhaus Bielefeld - Johannesstift ( Site 1307)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0521 772 75504
-
Solingen, North Rhine-Westphalia, Duitsland, 42699
- Werving
- Krankenhaus Bethanien ( Site 1303)
-
Contact:
- Study Coordinator
- Telefoonnummer: +49212636661
-
-
-
-
National Capital Region
-
Pasig, National Capital Region, Filippijnen, 1600
- Werving
- The Medical City ( Site 3507)
-
Contact:
- Study Coordinator
- Telefoonnummer: (02)6356789 loc 5083
-
Quezon City, National Capital Region, Filippijnen, 1100
- Werving
- Lung Center of the Philippines-Pulmonary, Critical Care and Sleep Medicine ( Site 3503)
-
Contact:
- Study Coordinator
- Telefoonnummer: +632 892 46101*1309
-
Quezon City, National Capital Region, Filippijnen, 1102
- Werving
- ST. LUKE'S MEDICAL CENTER-Medical oncology ( Site 3501)
-
Contact:
- Study Coordinator
- Telefoonnummer: +63287230101
-
Quezon City, National Capital Region, Filippijnen, 1100
- Actief, niet wervend
- Veterans Memorial Medical Center-Section of Oncology ( Site 3505)
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankrijk, 06000
- Werving
- Centre Hospitalier Universitaire de Nice - Hopital Pasteur ( Site 1108)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33492038281
-
-
Bourgogne-Franche-Comté
-
Dijon, Bourgogne-Franche-Comté, Frankrijk, 21000
- Werving
- Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1103)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33380293772
-
-
Gard
-
Nîmes, Gard, Frankrijk, 30029
- Werving
- Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 1106)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33 4 66 68 32 21
-
-
Nord
-
Valenciennes, Nord, Frankrijk, 59304
- Werving
- Clinique Teissier Groupe ( Site 1100)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33327142337
-
-
Puy-de-Dome
-
Clermont-Ferrand, Puy-de-Dome, Frankrijk, 63003
- Werving
- Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1101)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33473278005
-
-
Vaucluse
-
Avignon, Vaucluse, Frankrijk, 84000
- Werving
- Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1104)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33432753333
-
-
Île-de-France Region
-
Boulogne-Billancourt, Île-de-France Region, Frankrijk, 92100
- Werving
- Hôpital Ambroise Paré-Department of Respiratory Diseases and Thoracic Oncology ( Site 1105)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33149095806
-
-
-
-
-
Tbilisi, Georgië, 0112
- Werving
- Todua Clinic, LLC ( Site 1204)
-
Contact:
- Study Coordinator
- Telefoonnummer: +995322575757
-
Tbilisi, Georgië, 0162
- Werving
- New Hospitals ( Site 1200)
-
Contact:
- Study Coordinator
- Telefoonnummer: +995 598 988 566
-
Tbilisi, Georgië, 0177
- Werving
- Cancer Research Centre. Mardaleishvili Medical Centre ( Site 1205)
-
Contact:
- Study Coordinator
- Telefoonnummer: +995322430100
-
Tbilisi, Georgië, 0102
- Werving
- American Hospital Network LLC ( Site 1208)
-
Contact:
- Study Coordinator
- Telefoonnummer: +995 571 300 705
-
Tbilisi, Georgië, 1206
- Voltooid
- Tbilisi Institute of Medicine ( Site 1206)
-
Tbilisi, Georgië, 0144
- Voltooid
- TSMU and Ingorokva High Medical Technology University Clinic LTD ( Site 1201)
-
Tbilisi, Georgië, 0159
- Werving
- "Institute of Clinical Oncology" LTD ( Site 1210)
-
Contact:
- Study Coordinator
- Telefoonnummer: +995599406920
-
-
Adjara
-
Batumi, Adjara, Georgië, 6000
- Werving
- High Technology Hospital Medcenter ( Site 1203)
-
Contact:
- Study Coordinator
- Telefoonnummer: +995596226060
-
Tbilisi, Adjara, Georgië, 0186
- Werving
- Caucasus Medical Centre ( Site 1202)
-
Contact:
- Study Coordinator
- Telefoonnummer: +995 597 550 140
-
-
Imereti
-
Kutaisi, Imereti, Georgië, 4600
- Werving
- JSC "Vian" ( Site 1211)
-
Contact:
- Study Coordinator
- Telefoonnummer: +995599705858
-
-
-
-
-
Thessaloniki, Griekenland, 570 10
- Werving
- G. Papanikolaou General Hospital-Pulmonary Clinic of Aristotle University of Thessaloniki ( Site 1405)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0030 231330787476
-
Thessaloniki, Griekenland, 570 01
- Werving
- European Interbalkan Medical Center ( Site 1404)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302310380000
-
-
Achaia
-
Pátrai, Achaia, Griekenland, 26504
- Werving
- UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1402)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302610999791
-
-
Attica
-
Athens, Attica, Griekenland, 115 27
- Werving
- THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1400)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302107700220
-
Athens, Attica, Griekenland, 115 22
- Werving
- Agios Savvas Regional Cancer Hospital-2nd Medical Oncology Department ( Site 1407)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302106409501
-
Marousi, Attica, Griekenland, 151 25
- Werving
- Athens Medical Center ( Site 1406)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302107464642
-
Piraeus, Attica, Griekenland, 185 37
- Werving
- Metaxa Cancer Hospital of Piraeus ( Site 1408)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302132079225
-
-
Thessaly
-
Larissa, Thessaly, Griekenland, 411 10
- Werving
- University General Hospital of Larissa-Oncology Clinic ( Site 1403)
-
Contact:
- Study Coordinator
- Telefoonnummer: +302413502124
-
-
-
-
Maharashtra
-
Mumbai, Maharashtra, Indië, 400012
- Werving
- Tata Memorial Hospital ( Site 3205)
-
Contact:
- Study Coordinator
- Telefoonnummer: 02224177000
-
Mumbai, Maharashtra, Indië, 400004
- Actief, niet wervend
- Sir H. N. Reliance Foundation Hospital and Research Centre ( Site 3201)
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indië, 110076
- Werving
- Indraprastha Apollo Hospitals-APOLLO RESEARCH INNOVATION ( Site 3203)
-
Contact:
- Study Coordinator
- Telefoonnummer: +919426166688
-
New Delhi, National Capital Territory of Delhi, Indië, 110029
- Werving
- AIIMS New Delhi Dept of Medicine ( Site 3206)
-
Contact:
- Study Coordinator
- Telefoonnummer: +91-9650629370
-
-
-
-
-
Padova, Italië, 35131
- Werving
- IOV - Istituto Oncologico Veneto IRCCS UOSD - Unità di ricerca clinica ( Site 1603)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390498215649
-
-
Campania
-
Naples, Campania, Italië, 80131
- Werving
- Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia clinica sperimentale Toraco-Polmonare ( Site 1607)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390811777029
-
-
Emilia-Romagna
-
Ravenna, Emilia-Romagna, Italië, 48121
- Werving
- Ospedale Santa Maria delle Croci ( Site 1606)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390544285247
-
-
Friuli Venezia Giulia
-
Aviano, Friuli Venezia Giulia, Italië, 33081
- Werving
- CRO-IRCCS-Clinical Oncology ( Site 1605)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390434309464
-
-
Lazio
-
Rome, Lazio, Italië, 00168
- Werving
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1601)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00390630156318
-
-
Lombardy
-
Milan, Lombardy, Italië, 20133
- Werving
- Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1600)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390223903829
-
Milan, Lombardy, Italië, 20141
- Werving
- Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1604)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390257489482
-
-
Napoli
-
Naples, Napoli, Italië, 80131
- Werving
- A.O.R.N. Ospedale dei Colli - Monaldi V.-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1602)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0817062652
-
-
Roma
-
Rome, Roma, Italië, 00144
- Werving
- Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1609)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390652662205
-
-
Tuscany
-
Livorno, Tuscany, Italië, 57124
- Werving
- Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno-UOC Oncologia Medica Livorno ( Site 1608)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00390586223416
-
-
-
-
-
Chiba, Japan, 260-8677
- Werving
- Chiba University Hospital ( Site 3322)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-43-222-7171
-
Hiroshima, Japan, 730-8518
- Werving
- Hiroshima City Hiroshima Citizens Hospital ( Site 3314)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-82-221-2291
-
Kumamoto, Japan, 861-4193
- Werving
- Saiseikai Kumamoto Hospital ( Site 3318)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-96-351-8000
-
Niigata, Japan, 951-8520
- Werving
- Niigata University Medical & Dental Hospital ( Site 3323)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-25-223-6161
-
Osaka, Japan, 545-8586
- Werving
- Osaka Metropolitan University Hospital ( Site 3321)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-6-6645-2121
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 466-8560
- Werving
- Nagoya University Hospital ( Site 3309)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-52-741-2111
-
Toyoake, Aichi-ken, Japan, 470-1192
- Werving
- Fujita Health University Hospital ( Site 3310)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-562-93-2111
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Werving
- National Cancer Center Hospital East ( Site 3303)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-4-7133-1111
-
-
Ehime
-
Matsuyam, Ehime, Japan, 719-0280
- Werving
- National Hospital Organization Shikoku Cancer Center ( Site 3315)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-89-999-1111
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japan, 811-1395
- Werving
- National Hospital Organization Kyushu Cancer Center ( Site 3316)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-92-541-3231
-
Kurume, Fukuoka, Japan, 830-0011
- Werving
- Kurume University Hospital ( Site 3317)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-942-35-3311
-
-
Gunma
-
Ōta, Gunma, Japan, 373-8550
- Werving
- Gunma Prefectural Cancer Center ( Site 3302)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-276-38-0771
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8543
- Werving
- Sapporo Medical University Hospital ( Site 3324)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-11-611-2111
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japan, 920-8641
- Werving
- Kanazawa University Hospital ( Site 3308)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-76-265-2000
-
-
Kanagawa
-
Kawasaki, Kanagawa, Japan, 216-8511
- Werving
- St. Marianna University Hospital ( Site 3320)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-44-977-8111
-
-
Mie-ken
-
Matsusaka, Mie-ken, Japan, 515-8544
- Werving
- Saiseikai Matsusaka Municipal Hospital ( Site 3311)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-598-23-1515
-
-
Miyagi
-
Natori-shi, Miyagi, Japan, 981-1293
- Werving
- Miyagi Cancer Center ( Site 3301)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-22-384-3151
-
Sendai, Miyagi, Japan, 981-0914
- Werving
- Sendai Kousei Hospital ( Site 3300)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-22-222-6181
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1191
- Werving
- Kansai Medical University Hospital ( Site 3312)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-72-804-0101
-
Takatsuki, Osaka, Japan, 569-8686
- Werving
- Osaka Medical and Pharmaceutical University Hospital ( Site 3313)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-72-683-1221
-
-
Saitama
-
Kitaadachi-gun, Saitama, Japan, 362-0806
- Werving
- Saitama Prefectural Cancer Center ( Site 3304)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-48-722-1111
-
-
Tokyo
-
Bunkyo, Tokyo, Japan, 113-8603
- Werving
- Nippon Medical School Hospital ( Site 3306)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-3-3822-2131
-
Shinjuku, Tokyo, Japan, 160-0023
- Werving
- Tokyo Medical University Hospital ( Site 3307)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-3-3342-6111
-
Shinjuku, Tokyo, Japan, 162-8655
- Werving
- National Center for Global Health and Medicine ( Site 3305)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-3-3202-7181
-
Ōta-ku, Tokyo, Japan, 143-8541
- Werving
- Toho University Omori Medical Center ( Site 3319)
-
Contact:
- Study Coordinator
- Telefoonnummer: +81-3-3762-4151
-
-
-
-
-
México, Mexico, 14080
- Werving
- Instituto Nacional de Cancerologia. ( Site 0608)
-
Contact:
- Study Coordinator
- Telefoonnummer: +525556280400
-
Oaxaca City, Mexico, 68000
- Werving
- Oaxaca Site Management Organization S.C. ( Site 0603)
-
Contact:
- Study Coordinator
- Telefoonnummer: +529515147056
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 06700
- Werving
- Arké SMO S.A. de C.V. ( Site 0602)
-
Contact:
- Study Coordinator
- Telefoonnummer: 5533345856
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 66460
- Werving
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 0600)
-
Contact:
- Study Coordinator
- Telefoonnummer: +528180883663
-
-
-
-
-
Utrecht, Nederland, 3584 CX
- Werving
- Universitair Medisch Centrum Utrecht ( Site 1704)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00318875555555
-
-
Gelderland
-
Ede, Gelderland, Nederland, 6716 RP
- Werving
- Ziekenhuis Gelderse Vallei ( Site 1705)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0318435499
-
Harderwijk, Gelderland, Nederland, 3844 DG
- Werving
- Ziekenhuis St. Jansdal-Poli Longziekten ( Site 1701)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0031341463504
-
-
Overijssel
-
Hengelo, Overijssel, Nederland, 7555 DL
- Werving
- Ziekenhuisgroep Twente, locatie Almelo ( Site 1706)
-
Contact:
- Study Coordinator
- Telefoonnummer: +31887087878
-
Zwolle, Overijssel, Nederland, 8025 AB
- Werving
- Isala, locatie Zwolle-Poli Longziekten ( Site 1700)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0031886243254
-
-
-
-
-
Auckland, Nieuw-Zeeland, 1023
- Werving
- Auckland City Hospital ( Site 3400)
-
Contact:
- Study Coordinator
- Telefoonnummer: +6493074949
-
-
-
-
Cherkasy Oblast
-
Cherkasy, Cherkasy Oblast, Oekraïne, 18009
- Voltooid
- COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 2209)
-
-
Chernivetska Oblast
-
Chernivtsi, Chernivetska Oblast, Oekraïne, 58013
- Werving
- Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" ( Site 2210)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380955077568
-
-
Dnipropetrovsk Oblast
-
Kryvyi Rih, Dnipropetrovsk Oblast, Oekraïne, 50000
- Werving
- Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 2215)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380973567855
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Oekraïne, 76018
- Werving
- Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 2202)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380978411455
-
-
Kirovohrad Oblast
-
Kropyvnytskyi, Kirovohrad Oblast, Oekraïne, 25011
- Werving
- Kirovohrad Regional Oncology Center-Chemotherapy department ( Site 2204)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380508412400
-
-
Kyivska Oblast
-
Kiev, Kyivska Oblast, Oekraïne, 03022
- Werving
- Medical Center "MedOffice Group" ( Site 2219)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380503858689
-
Kyiv, Kyivska Oblast, Oekraïne, 03039
- Werving
- LLC Clinic Verum Expert ( Site 2223)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380443835959
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Oekraïne, 79059
- Werving
- Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 2217)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380506749772
-
-
Rivne Oblast
-
Rivne, Rivne Oblast, Oekraïne, 33007
- Voltooid
- Rivne Regional Clinical Hospital ( Site 2205)
-
Rivne, Rivne Oblast, Oekraïne, 33010
- Werving
- ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 2920)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380362633075
-
-
Vinnytsia Oblast
-
Vinnytsia, Vinnytsia Oblast, Oekraïne, 21029
- Werving
- Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 2211)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380953105783
-
-
Volyn Oblast
-
Lutsk, Volyn Oblast, Oekraïne, 43018
- Werving
- ME Volyn Regional Clinical Hospital of the Volyn Regional Council ( Site 2216)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380503782998
-
-
-
-
-
Vienna, Oostenrijk, 1210
- Werving
- Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2400)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0043 1 27700 72212
-
-
Styria
-
Graz, Styria, Oostenrijk, 8036
- Werving
- Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 2401)
-
Contact:
- Study Coordinator
- Telefoonnummer: 004331638512183
-
-
-
-
-
Lima, Peru, 15036
- Werving
- IPOR Instituto Peruano de Oncología & Radioterapia ( Site 4301)
-
Contact:
- Study Coordinator
- Telefoonnummer: 511 2241598 anex 121
-
-
-
-
Lesser Poland Voivodeship
-
Gorlice, Lesser Poland Voivodeship, Polen, 38-300
- Voltooid
- Szpital Specjalistyczny im. Henryka Klimontowicza ( Site 1801)
-
Krakow, Lesser Poland Voivodeship, Polen, 30-727
- Voltooid
- Pratia MCM Krakow ( Site 1808)
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-090
- Werving
- Uniwersytecki Szpital Kliniczny nr 4 w Lublinie ( Site 1805)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48 814485180
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 02-781
- Werving
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1800)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48225462336
-
-
Podkarpackie Voivodeship
-
Przemyśl, Podkarpackie Voivodeship, Polen, 37-700
- Werving
- Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1804)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48166775000
-
-
Warmian-Masurian Voivodeship
-
Olsztyn, Warmian-Masurian Voivodeship, Polen, 10-357
- Werving
- Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie ( Site 1809)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48895322978
-
-
-
-
-
Brasov, Roemenië, 500052
- Werving
- SC ONCO CARD SRL ( Site 1995)
-
Contact:
- Study Coordinator
- Telefoonnummer: +40268 994
-
Bucharest, Roemenië, 077190
- Werving
- SC MNT HEALTHCARE EUROPE SRL ( Site 1991)
-
Contact:
- Study Coordinator
- Telefoonnummer: +40722927377
-
Cluj-Napoca, Roemenië, 400015
- Werving
- Institutul Oncologic Cluj-Oncologie Medicala ( Site 1999)
-
Contact:
- Study Coordinator
- Telefoonnummer: +40264598362
-
Suceava, Roemenië, 720214
- Werving
- Sigmedical Services SRL ( Site 1997)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4 0330 803 483
-
-
Bucharest
-
Bucharest, Bucharest, Roemenië, 020335
- Werving
- Centrul de Diagnostic si Tratament Provita. ( Site 1992)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4021.9432
-
-
Dolj
-
Craiova, Dolj, Roemenië, 200542
- Werving
- Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1994)
-
Contact:
- Study Coordinator
- Telefoonnummer: +40731604432
-
-
Timiș County
-
Timișoara, Timiș County, Roemenië, 300239
- Werving
- Cabinet Medical Oncomed ( Site 1998)
-
Contact:
- Study Coordinator
- Telefoonnummer: +40356460995
-
-
-
-
-
Barcelona, Spanje, 08035
- Werving
- Hospital Universitari Vall d Hebron ( Site 2010)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34 932 543 450
-
Madrid, Spanje, 28040
- Werving
- Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 2017)
-
Contact:
- Study Coordinator
- Telefoonnummer: 34915504800x253900
-
Madrid, Spanje, 28006
- Werving
- Hospital Universitario La Princesa ( Site 2020)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34915202200
-
Málaga, Spanje, 29010
- Werving
- Hospital Universitario Virgen de la Victoria ( Site 2021)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0034671594566
-
Seville, Spanje, 41009
- Werving
- Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2015)
-
Contact:
- Study Coordinator
- Telefoonnummer: 34954712941
-
-
Barcelona
-
Vic, Barcelona, Spanje, 08500
- Werving
- H. General de Vic ( Site 2022)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34937027732
-
-
Las Palmas
-
Las Palmas de Gran Canaria, Las Palmas, Spanje, 35001
- Werving
- Hospital Insular de Gran Canaria-Oncology ( Site 2019)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34 928441738
-
-
Madrid, Comunidad de
-
Leganés, Madrid, Comunidad de, Spanje, 28911
- Werving
- Hospital Universitario Severo Ochoa ( Site 2024)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34914818000
-
Madrid, Madrid, Comunidad de, Spanje, 28009
- Werving
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2012)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34 915868115
-
-
Malaga
-
Málaga, Malaga, Spanje, 29011
- Werving
- H.R.U Málaga - Hospital General-Oncology ( Site 2014)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34 951308130
-
-
-
-
-
Adana, Turkije (Türkiye), 01140
- Werving
- Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2107)
-
Contact:
- Study Coordinator
- Telefoonnummer: +90 322 456 19 00
-
Ankara, Turkije (Türkiye), 06010
- Werving
- SBU GULHANE EGITIM VE ARASTIRMA HASTANESI Onkoloji ( Site 2104)
-
Contact:
- Study Coordinator
- Telefoonnummer: +905058726378
-
Ankara, Turkije (Türkiye), 06230
- Werving
- Hacettepe Universite Hastaneleri-oncology hospital ( Site 2101)
-
Contact:
- Study Coordinator
- Telefoonnummer: +90 312 305 10 80
-
Ankara, Turkije (Türkiye), 06520
- Werving
- Memorial Ankara Hastanesi-Medical Oncology ( Site 2106)
-
Contact:
- Study Coordinator
- Telefoonnummer: +903122536666
-
Ankara, Turkije (Türkiye), 06800
- Werving
- Ankara Bilkent Şehir Hastanesi ( Site 2100)
-
Contact:
- Study Coordinator
- Telefoonnummer: +903125526000
-
Istanbul, Turkije (Türkiye), 34214
- Werving
- Medipol Mega Universite Hastanesi-oncology ( Site 2105)
-
Contact:
- Study Coordinator
- Telefoonnummer: +902124447044
-
Istanbul, Turkije (Türkiye), 34722
- Werving
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2103)
-
Contact:
- Study Coordinator
- Telefoonnummer: +902166065200
-
Sakarya, Turkije (Türkiye), 54290
- Werving
- Sakarya Training and Research Hospital ( Site 2109)
-
Contact:
- Study Coordinator
- Telefoonnummer: +902648884000
-
-
İzmir
-
Balçova, İzmir, Turkije (Türkiye), 35340
- Werving
- Dokuz Eylul Universitesi Hastanesi ( Site 2108)
-
Contact:
- Study Coordinator
- Telefoonnummer: +902323434343
-
Bornova, İzmir, Turkije (Türkiye), 35100
- Werving
- Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2102)
-
Contact:
- Study Coordinator
- Telefoonnummer: +905322202675
-
-
-
-
Buckinghamshire
-
Milton Keynes, Buckinghamshire, Verenigd Koninkrijk, MK6 5LD
- Werving
- Milton Keynes Hospital ( Site 2304)
-
Contact:
- Study Coordinator
- Telefoonnummer: 01908 997609
-
-
Devon
-
Exeter, Devon, Verenigd Koninkrijk, EX2 5DW
- Werving
- Royal Devon & Exeter Hospital-Oncology ( Site 2302)
-
Contact:
- Study Coordinator
- Telefoonnummer: +44 (0) 1392 402869
-
-
-
-
California
-
Bakersfield, California, Verenigde Staten, 93309
- Werving
- CBCC Global Research, Inc. ( Site 0123)
-
Contact:
- Study Coordinator
- Telefoonnummer: 661-322-2206
-
Beverly Hills, California, Verenigde Staten, 90211
- Werving
- Beverly Hills Cancer Center ( Site 0116)
-
Contact:
- Study Coordinator
- Telefoonnummer: 310-432-8955
-
-
Connecticut
-
Stamford, Connecticut, Verenigde Staten, 06902
- Werving
- Stamford Hospital ( Site 0136)
-
Contact:
- Study Coordinator
- Telefoonnummer: 877-233-9355
-
-
Florida
-
Miami Beach, Florida, Verenigde Staten, 33140
- Voltooid
- Mount Sinai Cancer Center ( Site 0137)
-
-
Illinois
-
Skokie, Illinois, Verenigde Staten, 60077
- Werving
- Orchard Healthcare Research Inc. ( Site 0115)
-
Contact:
- Study Coordinator
- Telefoonnummer: 224-534-7580
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64108
- Werving
- Truman Medical Center ( Site 0126)
-
Contact:
- Study Coordinator
- Telefoonnummer: 816-404-4093
-
Springfield, Missouri, Verenigde Staten, 65807
- Werving
- Cox Medical Center North ( Site 0133)
-
Contact:
- Study Coordinator
- Telefoonnummer: 417-875-3000
-
-
Montana
-
Billings, Montana, Verenigde Staten, 59102
- Werving
- St. Vincent Frontier Cancer Center-Research ( Site 0105)
-
Contact:
- Study Coordinator
- Telefoonnummer: 402-238-6685
-
-
New Jersey
-
Morristown, New Jersey, Verenigde Staten, 07960
- Voltooid
- Atlantic Health System Morristown Medical Center ( Site 0121)
-
-
New York
-
Albany, New York, Verenigde Staten, 12206
- Werving
- New York Oncology Hematology, P.C. ( Site 0132)
-
Contact:
- Study Coordinator
- Telefoonnummer: 518-489-3612
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Werving
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)
-
Contact:
- Study Coordinator
- Telefoonnummer: 513-556-6000
-
Kettering, Ohio, Verenigde Staten, 45429
- Voltooid
- Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106)
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Verenigde Staten, 17601
- Werving
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134)
-
Contact:
- Study Coordinator
- Telefoonnummer: 717-544-9400
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Oncology Consultants P.A. ( Site 0113)
-
Contact:
- Study Coordinator
- Telefoonnummer: 713-600-0900
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53715
- Werving
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0129)
-
Contact:
- Study Coordinator
- Telefoonnummer: 608-410-2767
-
-
-
-
-
Incheon, Zuid -Korea, 22332
- Werving
- Inha University Hospital ( Site 3610)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82328901038
-
Seoul, Zuid -Korea, 02447
- Werving
- Kyung Hee University Hospital ( Site 3605)
-
Contact:
- Study Coordinator
- Telefoonnummer: 82-2-958-8511
-
Seoul, Zuid -Korea, 08308
- Werving
- Korea University Guro Hospital ( Site 3601)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82226261914
-
Seoul, Zuid -Korea, 03312
- Werving
- The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 3608)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82220304340
-
Seoul, Zuid -Korea, 02841
- Werving
- Korea University Anam Hospital ( Site 3609)
-
Contact:
- Study Coordinator
- Telefoonnummer: +8229206409
-
-
Incheon
-
Bupyeong-gu, Incheon, Zuid -Korea, 21431
- Werving
- The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 3606)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82-32-280-6474
-
-
Jeonranamdo
-
Hwasun, Jeonranamdo, Zuid -Korea, 58128
- Voltooid
- Chonnam National University Hwasun Hospital-Pulmonology ( Site 3604)
-
-
Kyonggi-do
-
Suwon, Kyonggi-do, Zuid -Korea, 16247
- Werving
- The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 3600)
-
Contact:
- Study Coordinator
- Telefoonnummer: 82-31-244-7983
-
-
Kyongsangnam-do
-
Yangsan, Kyongsangnam-do, Zuid -Korea, 50612
- Werving
- Pusan National University Yangsan Hospital-Lung Cancer Clinic ( Site 3603)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82-55-360-1415
-
-
Taegu-Kwangyokshi
-
Daegu, Taegu-Kwangyokshi, Zuid -Korea, 42415
- Werving
- Yeungnam University Hospital ( Site 3607)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82536203848
-
Daegu, Taegu-Kwangyokshi, Zuid -Korea, 42601
- Werving
- Keimyung University Dongsan Hospital ( Site 3611)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82532587737
-
-
Taejon-Kwangyokshi
-
Junggu, Taejon-Kwangyokshi, Zuid -Korea, 35015
- Werving
- Chungnam national university hospital ( Site 3602)
-
Contact:
- Study Coordinator
- Telefoonnummer: 82-42-257-5753
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
- Has histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
- Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection or curative chemotherapy/radiation as determined by a multidisciplinary tumor board and/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a, M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8
- Provides an archival tumor sample (≤5 years) or newly obtained core, incisional, or excisional biopsy or fine needle aspirate (FNA) of a tumor lesion, not previously irradiated to enable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutation status, programmed cell death ligand 1 (PD-L1) status, and biomarker research
- If have had adverse events (AEs) due to previous anticancer therapies, must have recovered to < Grade 1 or baseline
- If human immunodeficiency virus (HIV)-infected, must have well controlled HIV on antiretroviral therapy (ART)
- If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
- If a participant has a history of Hepatitis C virus (HCV) infection, HCV viral load is undetectable
Exclusion Criteria:
- Has diagnosis of small cell lung cancer. For mixed tumors, if small cell elements are present, the participant is ineligible
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
- Has known history of, or active, neurologic paraneoplastic syndrome
- Has an active infection requiring systemic therapy, with exceptions
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Has received prior systemic anticancer therapy for their locally advanced or metastatic NSCLC
- Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
- Has received radiotherapy to non-central nervous system (CNS) disease within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not required corticosteroids, and not have had radiation pneumonitis
- Has known active CNS metastases and/or carcinomatous meningitis
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has active autoimmune disease that has required systemic treatment in the past 2 years
- Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Is HIV-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has history of allogenic tissue/solid organ transplant
- Has not fully recovered from any effects of major surgical procedure
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Calderasib with Pembrolizumab
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (q3w) for up to 35 cycles and calderasib by oral tablets until discontinuation criterion is met. |
IV infusion
Andere namen:
Oral tablets
Andere namen:
|
|
Actieve vergelijker: Placebo with Pembrolizumab
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (q3w) for up to 35 cycles and placebo by oral tablets once daily until discontinuation criterion is met. |
IV infusion
Andere namen:
Oral tablets |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS)
Tijdsspanne: Up to approximately 42 months
|
PFS is defined as the time from randomization until either documented disease progression per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause, whichever occurs first. PFS as determined by blinded independent central review (BICR) will be presented. |
Up to approximately 42 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Survival
Tijdsspanne: Up to approximately 57 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 57 months
|
|
Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 42 months
|
ORR is defined as the percentage of participants with Complete Response or Partial Response per RECIST1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented. |
Up to approximately 42 months
|
|
Duration of Response (DOR)
Tijdsspanne: Up to approximately 42 months
|
For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by BICR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. |
Up to approximately 42 months
|
|
Number of Participants Who Experience One or More Adverse Event (AEs)
Tijdsspanne: Up to approximately 80 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be presented. |
Up to approximately 80 months
|
|
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Tijdsspanne: Up to approximately 80 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 80 months
|
|
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the score of EORTC QLQ-C30 Items 29 and 30 will be presented. Higher scores indicate a better overall health status. |
Baseline and Up to approximately 24 months
|
|
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C30 Items 1-5 will be presented. Higher scores indicate a better level of functioning. |
Baseline and Up to approximately 24 months
|
|
Change From Baseline in EORTC QLQ-C30 Role Functioning (Items 6-7) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C30 Items 6-7 will be presented. Higher scores indicate a better level of functioning. |
Baseline and Up to approximately 24 months
|
|
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant response to the question "Were you short of breath?" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C30 Item 8 will be presented. A higher score indicates a worse level of dyspnea. |
Baseline and Up to approximately 24 months
|
|
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer Module (EORTC QLQ-LC13) Cough (Item 31) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
The EORTC QLQ-C13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question "Have you coughed?" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C13 Item 31 will be presented. A higher score indicates more frequent coughing. |
Baseline and Up to approximately 24 months
|
|
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question "Have you had pain in your chest?" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C13 Item 40 will be presented. A higher score indicates a worse level of chest pain. |
Baseline and Up to approximately 24 months
|
|
Time to Deterioration (TTD) in EORTC-QLQ-C30 Global Health Status (Item 29) Quality of Life (Item 30) Combined Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
TTD is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in global health status (GHS) and quality of life (QoL) (EORTC QLQ-C30 Items 29 and 30) score. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10 point negative change (decrease) from baseline in GHS and QoL, will be presented. A longer TTD indicates a better outcome. |
Baseline and Up to approximately 24 months
|
|
TTD in EORTC-QLQ-C30 Physical Functioning (Items 1-5) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
TTD is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10 point negative change (decrease) from baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome. |
Baseline and Up to approximately 24 months
|
|
TTD in EORTC-QLQ-C30 Role Functioning (Items 6-7) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
TTD is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in role functioning (EORTC QLQ-C30 Items 6 and 7) score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10 point negative change (decrease) from baseline in role functioning score, will be presented. A longer TTD indicates a better outcome. |
Baseline and Up to approximately 24 months
|
|
TTD in EORTC-QLQ-C30 Dyspnea (Item 8) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
TTD is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in dyspnea (EORTC QLQ-C30 Item 8) score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant response to the question "Were you short of breath?" is scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10 point negative change (decrease) from baseline in dyspnea score, will be presented. A longer TTD indicates a better outcome. |
Baseline and Up to approximately 24 months
|
|
TTD in EORTC QLQ-LC13 Cough (Item 31) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
TTD is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in cough (EORTC QLQ-C13 Item 31) score. The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question "Have you coughed?" is scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10 point negative change (decrease) from baseline in cough score, will be presented. A longer TTD indicates a better outcome. |
Baseline and Up to approximately 24 months
|
|
TTD in EORTC QLQ-LC13 Chest Pain (Item 40) Score
Tijdsspanne: Baseline and Up to approximately 24 months
|
TTD is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in chest pain (EORTC QLQ-C13 Item 40) score. The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question "Have you had pain in your chest?" is scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10 point negative change (decrease) from baseline chest pain score, will be presented. A longer TTD indicates a better outcome. |
Baseline and Up to approximately 24 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Medical Director, Merck Sharp & Dohme LLC
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1084-004
- MK-1084-004 (Andere identificatie: MSD)
- U1111-1296-8093 (Register-ID: UTN)
- jRCT2031240213 (Register-ID: jRCT)
- PHRR241128-007796 (Register-ID: PHRR)
- 2023-507776-42-00 (Register-ID: EU CT)
- KANDLELIT-004 (Andere identificatie: MSD)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .